Oligometastatic Cancers and SBRT
This session aims to provide a comprehensive update on the latest advancements and evidence-based practices in the management of oligometastatic/oligoprogressive disease. It will include a didactic portion, case studies, and interactive discussions. Participants will enhance their understanding of the biological underpinnings, diagnostic criteria and therapeutic strategies for oligometastatic/oligoprogressive disease. Emphasis is placed on the integration of modern radiation therapy techniques, systemic therapies and multidisciplinary approaches to improve patient outcomes.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify the appropriate indication for ablative radiotherapy in oligometastatic/oligoprogressive cancer.
- Identify the appropriate dose, volume, and technique for treatment of oligometastatic/oligoprogressive cancer.
- Advocate in the tumor board and work with other colleagues for optimizing local therapy for patients with oligometastatic/oligoprogressive cancer.
Faculty:
A list of all meeting faculty and Individual presenter disclosures can be found on the Schedule of Events page.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.